Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia

Sunovion Pharmaceuticals and PsychoGenics have secured the breakthrough therapy designation from the US Food and Drug Administration (FDA) for their jointly owned psychotropic agent SEP-363856 for the treatment of schizophrenia.